Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Arad

Showing results (1-10 of 144) with videos related to

Pageof 15
Sort By:
Journal of Muscle Research and Cell Motility|September 9, 2020
Molecular adaptation to calsequestrin 2 (CASQ2) point mutations leading to catecholaminergic polymorphic ventricular tachycardia (CPVT): comparative analysis of R33Q and D307H mutantsGiorgia Valle, Michael Arad, Pompeo Volpe
Current Problems in Cardiology|December 11, 2008
Catecholaminergic polymorphic ventricular tachycardia from bedside to bench and beyondGuy Katz, Michael Arad, Michael Eldar
The Israel Medical Association Journal : IMAJ|June 30, 2005
Genetic ideology of dilated cardiompathyMichael Arad, Hadas Lahat, Dov Freimark
Harefuah|December 15, 2011
[Hospice for end-stage heart failure and its relevance to Israel]Yael Potashnik-Peled, Michael Arad, Dov Freimark
Pharmacology & Therapeutics|August 23, 2015
Inherited cardiomyopathies--Novel therapiesDror B Leviner, Edith Hochhauser, Michael Arad
Human Molecular Genetics|September 28, 2002
Phenotypic diversity in hypertrophic cardiomyopathyMichael Arad, J G Seidman, Christine E Seidman
European Journal of Preventive Cardiology|February 8, 2017
Blood pressure dynamics during exercise rehabilitation in heart failure patientsIdan Hecht, Michael Arad, Dov Freimark, et al.
Molecular and Cellular Biochemistry|April 16, 2002
Modulation of cardiac A1-adenosine receptors in rats following treatment with agents affecting heart rateNissim Balas, Michael Arad, Babeth Rabinowitz, et al.
Circulation Research|March 3, 2007
AMP-activated protein kinase in the heart: role during health and diseaseMichael Arad, Christine E Seidman, J G Seidman
Prostaglandins & Other Lipid Mediators|May 16, 2020
Therapeutic approaches to diabetic cardiomyopathy: Targeting the antioxidant pathwayMichael Arad, Maayan Waldman, Nader G Abraham, et al.
Pageof 15

Showing results (1-10 of 144) with videos related to

Sort By:
Pageof 15
Journal of Muscle Research and Cell Motility|September 9, 2020
Molecular adaptation to calsequestrin 2 (CASQ2) point mutations leading to catecholaminergic polymorphic ventricular tachycardia (CPVT): comparative analysis of R33Q and D307H mutantsGiorgia Valle, Michael Arad, Pompeo Volpe
Current Problems in Cardiology|December 11, 2008
Catecholaminergic polymorphic ventricular tachycardia from bedside to bench and beyondGuy Katz, Michael Arad, Michael Eldar
The Israel Medical Association Journal : IMAJ|June 30, 2005
Genetic ideology of dilated cardiompathyMichael Arad, Hadas Lahat, Dov Freimark
Harefuah|December 15, 2011
[Hospice for end-stage heart failure and its relevance to Israel]Yael Potashnik-Peled, Michael Arad, Dov Freimark
Pharmacology & Therapeutics|August 23, 2015
Inherited cardiomyopathies--Novel therapiesDror B Leviner, Edith Hochhauser, Michael Arad
Human Molecular Genetics|September 28, 2002
Phenotypic diversity in hypertrophic cardiomyopathyMichael Arad, J G Seidman, Christine E Seidman
European Journal of Preventive Cardiology|February 8, 2017
Blood pressure dynamics during exercise rehabilitation in heart failure patientsIdan Hecht, Michael Arad, Dov Freimark, et al.
Molecular and Cellular Biochemistry|April 16, 2002
Modulation of cardiac A1-adenosine receptors in rats following treatment with agents affecting heart rateNissim Balas, Michael Arad, Babeth Rabinowitz, et al.
Circulation Research|March 3, 2007
AMP-activated protein kinase in the heart: role during health and diseaseMichael Arad, Christine E Seidman, J G Seidman
Prostaglandins & Other Lipid Mediators|May 16, 2020
Therapeutic approaches to diabetic cardiomyopathy: Targeting the antioxidant pathwayMichael Arad, Maayan Waldman, Nader G Abraham, et al.
Pageof 15